Gene Synthesis .pdf
Original filename: Gene Synthesis.pdf
Author: Chris Moriarty
This PDF 1.5 document has been generated by Microsoft® Word 2010, and has been sent on pdf-archive.com on 04/06/2017 at 10:20, from IP address 117.205.x.x.
The current document download page has been viewed 265 times.
File size: 120 KB (1 page).
Privacy: public file
Download original PDF file
Fusion Antibodies Ltd (UK) and Synbio Technologies Co. Ltd (China/USA)
announce a commercial partnership to support biologic drug development in
FOR IMMEDIATE RELEASE
Fusion Antibodies Ltd (Belfast, UK) and Synbio Technologies Co Ltd (China/USA), today
announce a commercial agreement whereby the companies will support academia,
biotech and pharma companies in China across the full spectrum of services required for
the discovery and development of biologic based drugs.
Fusion Antibodies, a biologic drug development contract research organisation (CRO)
founded in Belfast UK in 2001, offers a suite of services from early discovery through to
antibody engineering and stable cell line development. They are particularly well known
for their antibody humanization capabilities utilising their proprietary CDRx™ platform.
Synbio Technologies is a DNA technology company which focuses on next generation
gene synthesis technology and its applications. The company‟s scientific capabilities
encompass areas such as DNA engineering, genome synthesis, pharmacogenomics,
microbiology, translational biology and the applications of synthetic biology. They have
developed the first integrated GPS (Genotype, Phenotype and Synotype) system aimed
to a quick and easy translation or reverse translation between “Genotype” and
“Phenotype” by using their proprietary “Synotype” platform.
“We are very excited with this new partnership,” Dr. Paul Kerr, Managing Director
of Fusion Antibodies stated. „‟We believe that bringing together Synbio Technologies
molecular biology expertise with Fusion Antibodies protein engineering capabilities will
bring significant benefits to the Chinese biologics development community. Through this
agreement Synbio‟s clients‟ will be able to move seamlessly from antibody discovery
through the key steps of gene synthesis and protein engineering to cGMP supply in
George Diao, VP for Business Development of Synbio Technologies said: „‟Fusion
Antibodies is the ideal partner as is has the right expertise and technology to help clients
move quickly in to clinical development. They have successfully completed over 75
humanization projects for biopharma clients globally and with 6 antibodies humanized
via their CDRx™ platform now in or entering clinical trials they have a proven track
record. Together we intend to replicate this success in China harnessing Synbio
Technologies local market knowledge and scientific expertise.